Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement component 3d (C3d) and its precursor complement component 3dg (C3dg) are stable, terminal degradation fragments of complement component 3 (C3) that are generated during the inactivation of C3b by factor I and its cofactors. Unlike upstream complement proteins that circulate freely, C3d and C3dg remain covalently attached to cell and tissue surfaces at sites of complement activation via a highly reactive thioester bond in their thioester-containing domain (TED). These fragments act as critical molecular bridges between innate and adaptive immunity by binding to complement receptor 2 (CR2/CD21) on B cells and follicular dendritic cells, thereby lowering the threshold for B-cell activation and enhancing antibody responses. They also interact with complement receptor 3 (CR3) on phagocytes to mediate cell clearance and opsonization.\n\nIn pathological states, dysregulated complement activation leads to excessive deposition of C3d and C3dg, contributing to tissue damage in autoimmune, inflammatory, and degenerative diseases, including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), lupus nephritis, age-related macular degeneration (AMD), and paroxysmal nocturnal hemoglobinuria (PNH). Because C3d and C3dg are stably anchored at sites of injury, they serve as ideal homing targets for tissue-targeted therapeutics. Drugs like AKB-097 (formerly ADX-097) and TT30 utilize anti-C3d antibodies or CR2-derived targeting domains fused to complement regulators (such as factor H) to selectively inhibit the alternative complement pathway locally at the site of disease. This targeted approach aims to provide robust therapeutic efficacy while sparing systemic complement activity, thereby minimizing the systemic infection risks associated with broad complement blockade.
Targeted delivery of complement regulators to sites of complement activation by binding to deposited C3d/C3dg fragments, thereby locally inhibiting the alternative complement pathway and preventing downstream membrane attack complex (MAC) formation.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement component 3d (C3d).